DelveInsight's "RNAi Technology Market Insights and Market Forecast - 2034" report offers a comprehensive view of market trends across North America, Europe, Asia-Pacific, and the Rest of World, tracing both historical performance and forward-looking projections.
Key Takeaways from the RNAi Technology Market Report
- The market stood at approximately USD 1.65 billion in 2025 and is expected to climb to USD 5.55 billion by 2034, reflecting a 14.4% CAGR between 2026 and 2034.
- siRNA remained the leading molecule type, capturing 68% of the market in 2025, as it forms the basis of nearly every approved RNAi therapeutic and late-stage clinical candidate.
- Drug discovery and development was the top application, representing 69% of the market in 2025, underscoring RNAi's central role in identifying and validating therapeutic targets.
- GalNAc conjugates led delivery technologies with a 46% share in 2025, having reshaped liver-directed delivery through convenient, infrequent subcutaneous dosing.
- Pharmaceutical and biotechnology companies made up 64% of the end-user segment in 2025, reflecting their outsized role in developing, manufacturing, and commercializing RNAi medicines.
- North America held the largest regional share at 45% of global revenue in 2025, while Asia-Pacific, led by China, is advancing at the fastest pace.
- Alnylam Pharmaceuticals secured FDA approval in March 2025 for AMVUTTRA (vutrisiran) in the cardiomyopathy of transthyretin-mediated amyloidosis, marking the first RNAi therapy proven to lower cardiovascular death, hospitalization, and urgent heart failure visits.
- Novartis AG entered a cardiovascular RNAi collaboration with Shanghai Argo in September 2025 valued at up to USD 4.165 billion.
- Companies active in this space include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Novo Nordisk A/S (Dicerna), Silence Therapeutics, Novartis AG, Ionis Pharmaceuticals, Thermo Fisher Scientific, Merck KGaA, Sirnaomics, and Sanofi S.A., among others.
RNAi Technology Market Segmentation Overview
- By Molecule Type: siRNA, miRNA, shRNA, Others
- By Application: Drug Discovery and Development, Therapeutics, Functional Genomics
- By Delivery Technology: GalNAc Conjugates, Lipid Nanoparticles, Polymer and Other Carriers, Viral Vectors
- By Therapeutic Area: Rare Genetic Disorders, Cardiometabolic Disorders, Oncology, Hepatic and Infectious Diseases, Neurological and Other Disorders
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research and Manufacturing Organizations
RNAi Technology Pipeline Momentum
The RNAi Technology Pipeline has broadened well beyond its original focus on hepatic disease, now spanning candidates aimed at rare genetic disorders, cardiometabolic conditions, oncology, and infectious disease. Arrowhead Pharmaceuticals' completion of phase 2 testing for ARO-HIF2 in renal cell carcinoma, and Sirnaomics' venture into aesthetic-medicine applications, show how far the pipeline has extended past its liver-focused beginnings.
RNAi Technology Market Outlook